Two days at the Kensington Conference and Events Center in London. Roughly 200 delegates and 25 speakers from across the digital health ecosystem – providers, payers, life sciences companies, and the vendors building the infrastructure underneath all three. The Digital Health World Congress is one of the more concentrated rooms in European health tech: fewer keynote stages than at a mega-conference, more conversations that go deep into a single implementation problem before moving on to the next.
Our COO, Andrew Yakibchuk, attended DHWC 2026 in London in May. What he came back with was a pattern, and it’s a familiar one to anyone who has tried to move a healthcare AI system from a working demo into a production environment.
Digital health has reached a specific inflection point: whether to invest in AI is no longer the debate. The debate is how to get a system from pilot to regulated, patient-facing production without breaking compliance, clinician trust, or the budget. That’s the signal DHWC 2026 made concrete. What follows is what the agenda covered, what the pattern means, and where we see the clearest engineering opportunities.
This article summarizes the key themes from Digital Health World Congress 2026, such as AI in life sciences, chronic disease management, healthcare data interoperability, responsible AI and compliance, and the shift from pilots to regulated deployment, and outlines the clearest engineering opportunities for healthcare organizations building production-grade AI.
- Interoperability determines what AI can actually do: Shared care records and standards-based data exchange are the preconditions for any AI use case that spans more than one system or care setting.
- Regulated AI requires provable quality, not post-hoc documentation: Moving from pilot to regulated scale means building compliance and explainability into the architecture from day one, not adding them before an audit.
- Chronic disease management is where patient-facing AI is furthest along: Continuous monitoring and digital therapeutics are ahead of acute-care AI in real-world deployment maturity.
- Trust between clinicians and AI outputs remains the adoption bottleneck: Even validated models see limited use when their outputs aren’t embedded in the clinical workflow that the care team already trusts.
Inside the DHWC 2026 Agenda: Five Trends Defining Digital Health
The DHWC 2026 program ran across keynote stages, a market-outlook panel, and a series of shorter, implementation-focused sessions over two days. Five themes ran through nearly all of it:
1. AI Accelerates the Life Sciences Value Chain
Several sessions framed AI’s impact on discovery-to-market timelines as a compression problem: the stages between a molecule and a marketed therapy are shortening as AI takes on more of the analytical load, from trial design to real-world evidence generation. Strategy-focused talks addressed the same shift from a different angle, looking at how life sciences organizations sequence AI investment against innovation priorities that are still evolving. The throughline: AI in life sciences is delivering its biggest wins earlier in the pipeline than most non-specialists expect.
2. Patient Engagement: AI and Chronic Disease Management Take the Spotlight
Some of the most concrete patient-facing sessions on the agenda addressed managing chronic disease with digital health – continuous monitoring, remote patient data, and intervention models built around conditions that unfold over months and years rather than single encounters. Other sessions on personalizing wellness to biometrics and on body composition tracking in a GLP-1-driven market extended the same theme: AI-powered patient engagement is maturing fastest where the data stream is continuous, and the intervention window is long — a pattern that’s reshaping chronic disease management technology across the board.
3. Interoperability and Shared Care Records as Healthcare’s Connective Tissue
The opening keynote — bridging the data divide between industrial data models and patient care — set an unusual but useful frame: healthcare interoperability looks structurally similar to problems already solved in industrial IoT, just with a much higher compliance bar. A session on digital infrastructure for shared care records addressed the same problem from the clinical side: what it actually takes to give a care team a coherent record when the underlying systems were never designed to share one. IoT case studies from the connected-health space rounded this theme out from the device side.
“The quality of the conversation at DHWC this year was different – almost nobody was still asking whether AI belongs in healthcare. They were asking how to get it through compliance, into the clinical workflow, and in front of a clinician who’d actually trust it.” — Andrew Yakibchuk, COO, Crunch-IS
4. Responsible, Secure AI for Regulated Healthcare Environments
One of the clearest statements at DHWC 2026 made the case that compliance-as-checkbox is no longer a credible position for AI vendors in health. A session on responsible AI in healthcare and medical decision-making walked through a European case study on the same problem: how to make HIPAA-compliant AI and AI-assisted clinical decisions defensible, not just accurate. A separate session on quantum-readiness for healthcare cybersecurity signaled that security planning horizons are extending well past current threat models.
5. Moving from Pilots to Regulated, Scalable Deployment
One session, addressing the move from AI pilots to regulated scale directly, tackled the gap this article keeps coming back to: the distance between a working pilot and a regulated AI deployment cleared for patient-facing use. Other sessions on digital inclusion — making sure AI-driven care models don’t leave patients without reliable connectivity or digital literacy behind — and on the evolution of digital health from apps to community-driven models rounded out a program that spent as much time on adoption and equity as it did on model performance.
Beyond the Sessions: Where Healthcare AI Adoption Really Stands
DHWC 2026 confirmed three gaps between where most healthcare organizations are with AI and where they need to be. Each requires a different kind of engineering to close, and each shows up repeatedly in Crunch-IS’s own healthcare engagements.
Closing the Clinical Data Readiness Gap
Clinical data is not clean tabular data. It’s structured EHR fields, free-text physician notes, imaging studies, wearable telemetry, and legacy exports, governed by HIPAA and, in the UK and EU contexts, NHS and GDPR requirements. Getting from that state to a model-ready dataset means mapping to clinical terminology standards — SNOMED CT, LOINC, ICD-10 — building FHIR-compliant data layers, and putting healthcare data governance controls in place before a model ever sees the data. This step is consistently underestimated at the start of digital health programs and rarely underestimated a second time.
From Pilot to Regulated Production: the Deployment Gap
Moving from a working pilot to a regulated, production-grade AI system requires MLOps for a healthcare discipline that goes well beyond model accuracy: monitoring for data and model drift, retraining pipelines, audit logging, and — critically in a clinical setting — outputs that are explainable to the clinicians and compliance staff who have to act on them. This is a design constraint built into the architecture from the outset, not documentation added before a review. It’s also where several of DHWC’s pilot-to-scale and compliance-focused talks converged: pilots that work rarely fail on model performance. They stall on the engineering required to operate safely at regulated scale.
Earning Clinician Trust in AI-assisted Decisions
The final constraint behind clinical decision support AI adoption is organizational, but it has a technical answer. Clinicians who’ve built judgment through years of direct patient contact don’t extend automatic trust to a model score, and they shouldn’t be expected to. The deployment pattern that works builds a trust loop into the system: AI outputs run alongside clinical judgment, disagreements get logged and reviewed, and the system earns adoption over successive cycles rather than being handed down as a mandate. Organizations that treat this as a change-management afterthought see low adoption even when the underlying model is accurate. The engineering work is in the interface between AI output and clinical decision-making, not in the model alone.
Where Digital Health AI Investment Is Headed Next
For the organizations furthest along at DHWC 2026, digital health innovation is a current engineering program with a defined path to regulated deployment — not a future investment category. For organizations earlier in the process, the near-term priority is the same as it’s been for the past two cycles: standards-based interoperability, clinical data governance, and a compliance architecture that’s designed in rather than layered on.
Four areas drew the clearest investment intent at DHWC 2026, both in the program and in the conversations on the floor:
- Generative AI for clinical documentation and administrative workflows
- AI-supported chronic disease and mental health management built on continuous patient data — the engagement layer behind our own NHS-integrated mental health platform
- Standards-based EHR and shared-care-record integration
- Clinical AI for trial screening, imaging, and video analytics, engineered for explainability and regulated deployment from the start
A shortage of ambition doesn’t hold healthcare AI adoption back. What separates the ones making real progress is data engineering done first, compliance built into architecture rather than bolted on, and a deployment approach that earns clinical trust instead of assuming it.
Conclusion
DHWC 2026 confirmed that digital health’s AI conversation has matured. Vendors and health systems alike are past the question of whether AI belongs in clinical and administrative workflows – the harder, more useful conversation now is how to get a system there safely, on standards-based data, in a form clinicians will actually use. The constraint isn’t ambition or budget. It’s the sequence of engineering work between data that exists today and AI systems that clinical teams trust every day, and the discipline to do that work in the right order.
That sequence — interoperable data infrastructure, compliance-first model development, production deployment, and trust built in at every stage — isn’t complicated to describe. It’s demanding to execute where data governance is strict, patient safety is non-negotiable, and the clinicians who need to trust the system’s outputs weren’t in the room when it was built. The organizations that make real progress over the next two to three years will be the ones working with engineering partners who understand that from the inside.
